All the Drug Class Drugs
Parathyroid hormone analogue. Teriparatide 250 mcg/ml. PRE-FILL. PEN (sol. for S.C. inj.):1,3. The usual. dose one S.C. inj. dly., in the thigh or lower abdomen. See lit.
Tmt . of postmenopaus. women with osteoporosis at high risk for frac., defined as a history of osteoporotic frac., multiple risk fact. for frac., or pts. who have failed or are intoler. to other available osteoporosis ther. In postmenopaus. women with osteoporosis, Teriparatide increas. BMD reduces the risk of vertebral and nonvertebral frac.
Indicated to incr. bone mass in men with prim. or hypogonadal osteoporosis at high risk for frac., defined as a history of osteoporotic frac., multiple risk fact. for frac., or pts. who have failed or are intoler.to other available osteoporosis ther.
Tmt. of men & women with osteoporosis associat. with sustained system. glucocorticoid ther. (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for frac., defined as a history of osteoporotic frac., multiple risk fact. for frac., or pts. who have failed or are intoler.to other available osteoporosis ther.
C/I: Hypersens.
Preg., lact.
Pts. with Paget’s dis., hypercalcem., metabol. bone dis., bone tumors.
Pts. that had underwent radiation ther. for the bones.
Severe renal impair.
Child. or a young pt. in the grow. stage.
Hyperparathyroidism.
Parathyroid hormone analogue. Teriparatide 20 mcg/dose. cartridge 2.4 ml X 1, starter box (cartridge 2.4 ml X 1 + Pen X 1)
20 mcg S.C. once a day
Tmt. of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intol. to other available osteoporosis ther. In postmenopausal women with osteoporosis this drug reduces the risk of vertebral and nonvertebral fractures . * To incr. bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, or who have failed or are intol. to other available osteoporosis ther. * Tmt. of men and women with osteoporosis associated with sustained systemic glucocorticoid ther. (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intol. to other available osteoporosis ther.
C/I: Hypersens. See lit.
Parathyroid hormone analogue. palopegteriparatide 0.3 mg/ml. pre -filled pen2 X 1.4/0.56/0.98 ml sol for SC inj.
Starting dose is 18 mcg once /d with dose adjustments in 3 mcg increm. thereafter every 7 days. The dose range is 6 to 60 mcg/d. Serum calcium concentr. must be monitored during titrat. Mainten. dose should be dose that achieves serum calcium within normal range, without need for active vit D or therap. doses of calcium. See full prescr. info.
Parathyroid hne.(PTH) replacement ther. for adults with chronic hypoparathyroidism
C/I: Hypersens.- pseudohypoparathyroidism
